SCHEMBL6323271

SCHEMBL6323271

CC(C)CC(C)NC(=O)c1c(-c2coc3ccccc23)noc1N

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.35
IKBKE Q14164 1/20 0.35
TBK1 Q9UHD2 1/20 0.35
RAB9A P51151 2/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
KMT2A Q03164 1/20 0.34
CA1 P00915 3/20 0.34
CA2 P00918 3/20 0.34
CA4 P22748 3/20 0.34
CA7 P43166 3/20 0.34
PSMB5 P28074 4/20 0.34
PSMB8 P28062 2/20 0.34
GRK2 P25098 1/20 0.33
MAOB P27338 1/20 0.33
MLYCD O95822 1/20 0.33
POLB P06746 1/20 0.32
TAS1R3 Q7RTX0 1/20 0.32
TAS1R1 Q7RTX1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316505 0.91 RAB9A (0.42) ACACBL3MBTL1RAB9AMEN1KMT2A
SCHEMBL885709 0.89 SMN1; SMN2 (0.35) ACACBL3MBTL1IKBKETBK1RAB9A
SCHEMBL6317238 0.89 L3MBTL1 (0.44) ACACBL3MBTL1IKBKETBK1RAB9A
SCHEMBL6323089 0.88 NPC1 (0.44) ACACBL3MBTL1RAB9AMEN1NPC1
SCHEMBL6323394 0.86 L3MBTL1 (0.37) L3MBTL1IKBKETBK1RAB9AKMT2A
SCHEMBL6323650 0.86 KMT2A (0.47) MEN1KMT2APOLBTAS1R3TAS1R1
SCHEMBL6315860 0.86 L3MBTL1 (0.38) ACACBL3MBTL1IKBKETBK1RAB9A
SCHEMBL6316467 0.85 L3MBTL1 (0.38) ACACBL3MBTL1IKBKETBK1MAOB
SCHEMBL6316589 0.85 KMT2A (0.43) L3MBTL1IKBKETBK1RAB9AMEN1
SCHEMBL6324905 0.85 TAS1R3 (0.42) L3MBTL1IKBKETBK1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 ACACB 1255/4885L3MBTL1 4176/4885IKBKE 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.